iqvia weight loss drug prescriptions q3 2024 semaglutide tirzepatide F.D.A. Approves New Obesity That Will Compete With Wegovy Outlook for obesity in 2025:
Description
However, individuals taking these medicationsespecially those with pre-existing diabetes or eye conditionsshould undergo regular eye exams and monitor for any changes in vision
Randomized trials show a low absolute incidence, but post-market surveillance suggests the real-world risk may be higher in vulnerable populations
Since 2022, the American Diabetes Association has updated its Standards of Care to recommend GLP1 receptor agonists as a firstline therapy for T2D 2 , eroding older and cheaper generics like metformin, which marks a momentous and fundamental change in treatment
Read the complete article that reviews the changes in semaglutide side effect prevalences in California hospitals associated with increased use of Ozempic and Wegovy: here.
